The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
 
Lajos Pusztai
Honoraria - Athenex; bioTheranostics; natera; OncoCyte
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Merck; Molecular Health; MSD Oncology; Roche
Research Funding - Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Gilead Sciences; GRAIL; Halozyme; HERON; Immunomedics; Ipsen; Lilly; Merck; Myriad Pharmaceuticals; Nektar; Novartis; Pfizer; Pharmacyclics; Pierre Fabre; Prime Oncology; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax; Synthon; Taiho Oncology; Takeda
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; GRAIL; Ipsen; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MedSIR; Nektar
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Bioinvent; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Gilead Sciences; Novartis; Pfizer; Roche
 
Rebecca Alexandra Dent
Honoraria - AstraZeneca; Eisai Europe; Lilly; MSD; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Eisai; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; Pfizer; Roche
 
Heather L. McArthur
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Genomic Health; Immunomedics; Lilly; Merck; Pfizer; Puma Biotechnology; Puma Biotechnology; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); ZIOPHARM Oncology (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Genentech; Immunomedics; Lilly; Lilly; Lilly; Lilly; Merck; Pfizer; Puma Biotechnology; Spectrum Pharmaceuticals
Other Relationship - Genomic Health; Lilly
 
Sherko Kuemmel
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; Seagen; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Jonas C. S. Bergh
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - UpToDate
 
Yeon Hee Park
Honoraria - Merck; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Novartis; Pfizer; Roche (Inst)
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); BMSi (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoSec (Inst); Roche (Inst); Seagen (Inst)
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Exact Sciences; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)
 
Masato Takahashi
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Pfizer
Research Funding - Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Taiho Pharmaceutical (Inst)
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art Tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art Tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Molecular Health (Inst); MSD Oncology (Inst); Mylan (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst)
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Fatima Cardoso
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline; IQvia; Macrogenics; Medscape; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen; Teva; touchIME
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Yalin Zhu
No Relationships to Disclose
 
Wilbur Pan
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Konstantinos Tryfonidis
No Relationships to Disclose
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)